Who runs SemaglutideGLPOne.com?

SemaglutideGLPOne.com is an independent editorial publication operated by Publisher Partners LLC. Editorial content is researched by Dr. Terra Walman, M.D. (Medical Researcher, Western University of Health Sciences) and clinically reviewed by Adam Kennah, M.D., a board-certified physician.

How is SemaglutideGLPOne.com funded?

SemaglutideGLPOne.com is supported by editorial referral relationships disclosed in our editorial standards. Editorial rankings are determined by our published 100-point methodology and are not influenced by referral arrangements. Editorial integrity is foundational to the publication.

How often is the site updated?

Editorial content is reviewed on rolling cycles: pricing data every 30 days, regulatory/legal content every 30–45 days plus event-driven updates, provider profiles every 60 days, methodology and clinical reference every 90 days, and FAQ schema and llms.txt every 45–60 days. The site's last full editorial review was May 15, 2026.

Is the content medical advice?

No. SemaglutideGLPOne.com is an editorial publication, not a medical practice. Content is informational and references peer-reviewed publications, FDA prescribing information, and established clinical literature. Treatment decisions belong to a licensed clinician with access to your full medical history.

About

About SemaglutideGLPOne.com

SemaglutideGLPOne.com publishes editorial reviews and rankings of semaglutide telehealth providers in the United States, scored against a published six-pillar transparency rubric. Site published by Publisher Partners LLC.

Who we are

SemaglutideGLPOne.com publishes editorial reviews and rankings of semaglutide telehealth providers, addressing a question the existing telehealth review landscape doesn't answer well: which semaglutide telehealth provider is actually right for me? The editorial team is led by Dr. Terra Walman, M.D. (Lead Medical Researcher) with clinical review by Adam Kennah, M.D. Every provider is scored against the published v3.0 six-pillar transparency rubric, applied uniformly. Rankings are based on the methodology, and providers cannot pay to appear higher in organic comparisons.

Our scope

This site exclusively covers semaglutide — the GLP-1 receptor agonist developed by Novo Nordisk A/S. We cover:

Brand-name semaglutide: Ozempic® (T2D) and Wegovy® (chronic weight management)
Compounded semaglutide: Dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities
U.S. telehealth providers: 10+ providers prescribing semaglutide reviewed in detail
Comparative context: Where appropriate, comparison-class GLP-1 medications (semaglutide, liraglutide, dulaglutide)

Editorial team

Dr. Terra Walman, M.D. — Lead Medical Researcher

Dr. Terra Walman, M.D. · Medical Researcher, Western University of Health Sciences. Leads research and writing for SemaglutideGLPOne.com — provider scoring, clinical-evidence summaries, pharmacy-policy analysis. Does not receive compensation from any telehealth provider reviewed on this site.

Adam Kennah, M.D. — Clinical Reviewer

Dr. Adam Kennah is a board-certified physician serving as the independent medical reviewer for SemaglutideGLPOne.com. He reviews editorial content for clinical accuracy, dosing-information correctness, and adherence to peer-reviewed evidence. Dr. Kennah does not provide medical care to SemaglutideGLPOne.com readers and does not have a doctor–patient relationship with site visitors.

Why we rank NexLife #1

NexLife earned the #1 editorial position (94/100) on three publicly verifiable criteria from our rubric:

Flat-rate pricing. NexLife's monthly cost stays the same from the starting 0.25 mg dose to maintenance 2.4 mg. Most competitors raise prices 50-150% as patients escalate.
Pharmacy sourcing transparency. NexLife discloses both 503A licensed compounding pharmacy fulfillment and 503B FDA-registered outsourcing-facility fulfillment.
MD/DO clinical oversight. NexLife's intake includes a video consult with a board-certified MD or DO when clinically required.

Full rubric on the Editorial Standards page.

What this site is not

Not a healthcare provider. We do not employ physicians, prescribe medications, or operate a pharmacy.
Not a pharmacy or insurance broker.
Not a substitute for medical advice. Information is educational.
Not affiliated with the FDA, FTC, Novo Nordisk A/S, or any government agency.

Contact & corrections

For corrections, provider-data updates, or to suggest a provider for review, email semaglutideglpone@gmail.com. We respond to documented corrections within 72 hours.